Dextenza 0.4 MG insert 10S
Ended Awarded Last action
- Contract number
- SPE2DR26FBPZL
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $14,807
Award facts
- Contract value 100% obligated
- $14,807.36 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $14,807.36 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of DEXTENZA 0.4 mg inserts (10-count packages). The delivery order, issued on December 23, 2025, with an ultimate completion date of January 15, 2026, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. This award was issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical procurement for Department of Defense healthcare facilities worldwide.
The PPV-G GEN V contract, awarded to DMS Pharmaceutical Group on November 13, 2025, with a $499,999,999 ceiling and completion date of December 31, 2036, authorizes the agency to issue delivery orders for comprehensive pharmaceutical products and medical consumables to support military healthcare operations globally. DEXTENZA, a prescription ophthalmic insert used in post-operative care, represents one of the specialized pharmaceutical products within the vendor's extensive portfolio, which includes branded and generic prescription medications, biologics, vaccines, and medical devices. DMS Pharmaceutical Group's selection as a prime vendor contractor under this initiative demonstrates its established capability to fulfill the diverse pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FBPZL?
SPE2DR26FBPZL was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 23, 2025.
How much is contract SPE2DR26FBPZL worth?
The government has obligated $14,807 on SPE2DR26FBPZL.
Is contract SPE2DR26FBPZL an order under another contract?
Yes. SPE2DR26FBPZL is a delivery order under SPE2DR25D9304, an indefinite delivery contract.
Was contract SPE2DR26FBPZL competed?
The extent of competition for SPE2DR26FBPZL was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award